Resistance to Ibrutinib

In the frontline, patient body mass index plays a prognostic role when using atezolizumab plus bevacizumab vs lenvatinib for patients with advanced hepatocellular carcinoma.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

During a Case-Based Roundtable® event, Misako Nagasaka, MD, discussed treatment for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

This breakthrough therapy designation of ziftomenib marks the first of its kinds in NPM1-mutant acute myeloid leukemia.

The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.